Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype

Human Pathology

Volumn 38, Issue 6, 2007, Pages 842-849

  Ogino, Shuji ^a,b,c   Kawasaki, Takako ^b   Ogawa, Akiyo ^b   Kirkner, Gregory J ^a   Loda, Massimo ^a,b,c   Fuchs, Charles S ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CIMP; Colon cancer; DNA methylation; FASN; MSI

Indexed keywords

B RAF KINASE; FATTY ACID SYNTHASE; K RAS PROTEIN; PROTEIN; PROTEIN CACNA1G; PROTEIN CDKN2A; PROTEIN CRABP1; PROTEIN MLH1; PROTEIN NEUROG1; PROTEIN P53; SOMATOMEDIN B; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ARTICLE; COLON; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PROTEIN EXPRESSION; SEX; STRATIFICATION; TUMOR LOCALIZATION;

COHORT STUDIES; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 34248170638     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2006.11.018     Document Type: Article

References (35)

1. Semenkovich C.F. Regulation of fatty acid synthase (FAS). Prog Lipid Res 36 (1997) 43-53
2. Motoshima H., Goldstein B.J., Igata M., et al. AMPK and Cell Proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574 (2006) 63-71
3. Kovacs P., Harper I., Hanson R.L., et al. A novel missense substitution (Val1483Ile) in the fatty acid synthase gene (FAS) is associated with percentage of body fat and substrate oxidation rates in nondiabetic Pima Indians. Diabetes 53 (2004) 1915-1919
4. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66 (2006) 5977-5980
5. Rossi S., Graner E., Febbo P., et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1 (2003) 707-715
6. Alo P.L., Visca P., Marci A., et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77 (1996) 474-482
7. Gansler T.S., Hardman III W., Hunt D.A., et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28 (1997) 686-692
8. Rashid A., Pizer E.S., Moga M., et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150 (1997) 201-208
9. Visca P., Alo P.L., Del Nonno F., et al. Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res 5 (1999) 4111-4118
10. Ogino S., Brahmandam M., Cantor M., et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 19 (2006) 59-68
11. Alli P.M., Pinn M.L., Jaffee E.M., et al. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24 (2005) 39-46
12. Li J.N., Gorospe M., Chrest F.J., et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 61 (2001) 1493-1499
13. Kridel S.J., Axelrod F., Rozenkrantz N., et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64 (2004) 2070-2075
14. Graner E., Tang D., Rossi S., et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5 (2004) 253-261
15. Giovannucci E., Ascherio A., Rimm E.B., et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122 (1995) 327-334
16. Giovannucci E., Colditz G.A., Stampfer M.J., et al. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 7 (1996) 253-263
17. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 4 (2004) 988-993
18. Samowitz W., Albertsen H., Herrick J., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 (2005) 837-845
19. Ogino S., Cantor M., Kawasaki T., et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55 (2006) 1000-1006
20. Weisenberger D.J., Siegmund K.D., Campan M., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38 (2006) 787-793
21. Shia J., Ellis N.A., Paty P.B., et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 27 (2003) 1407-1417
22. Alexander J., Watanabe T., Wu T.T., et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158 (2001) 527-535
23. Slattery M.L., Potter J.D., Curtin K., et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61 (2001) 126-130
24. Ogino S., Kawasaki T., Brahmandam M., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8 (2006) 209-217
25. Colditz G.A., and Hankinson S.E. The nurses' health study: lifestyle and health among women. Nat Rev Cancer 5 (2005) 388-396
26. Giovannucci E., Liu Y., Rimm E.B., et al. Prospective study of predictors of vitamin d status and cancer incidence and mortality in men. J Natl Cancer Inst 98 (2006) 451-459
27. Ogino S., Kawasaki T., Kirkner G.J., et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8 (2006) 582-588
28. Ogino S., Odze R.D., kawasaki T., et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 30 (2006) 1175-1183
29. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7 (2005) 413-421
30. Eads C.A., Danenberg K.D., Kawakami K., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28 (2000) E32
31. Widschwendter M., Siegmund K.D., Muller H.M., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64 (2004) 3807-3813
32. Ogino S., Brahmandam M., kawasaki T., et al. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 8 (2006) 458-464
33. Camp R.L., Charette L.A., and Rimm D.L. Validation of tissue microarray technology in breast carcinoma. Lab Invest 80 (2000) 1943-1949
34. Ogino S., Kawasaki T., Kirkner G.J., et al. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 20 (2007) 15-22
35. Ogino S., kawasaki T., Kirkner G.J., et al. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 210 (2006) 147-154